Navigation Links
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Date:5/20/2008

NOVATO, Calif., May 20 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The study is expected to conclude enrollment in the fourth quarter of 2008.

"We are dedicated to serving the PKU community and hope to address the entire spectrum of PKU patients between PEG-PAL and Kuvan. We believe PEG-PAL holds tremendous potential to bring blood Phe down to normal levels and may help patients who either do not respond to Kuvan or who wish to reduce blood Phe levels beyond what is possible with Kuvan," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "Positive preclinical data shows sustained decreases in blood Phe levels in PKU mice without any notable safety concerns and we hope to see the same results in humans."

The Phase 1 clinical trial is an open-label, multi-center study to be conducted in approximately 35 PKU patients in a series of seven dose- escalating cohorts ranging from 0.001 to 1.0 mg/kg, with each cohort receiving a single dose, and a 6-week follow-up period.

The primary objective of the study is to assess the safety and tolerability of single, subcutaneous injections of PEG-PAL in subjects with PKU. The secondary objectives of the study are to evaluate the pharmacokinetics of single, subcutaneous injections of PEG-PAL administered at escalating doses and to evaluate the effect of PEG-PAL on blood Phe concentrations in subjects with PKU.

About PEG-PAL

PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) is an investigational enzyme substitution therapy for the treatment of PKU. Pharmacology studies conducted in the PKU mouse model demonstrated that weekly subcutaneous administrations of PEG-PAL resulted in a significant and stable decrease of plasma phenylalanine. BioMar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. BioMarin Announces FDA Approval for Kuvan
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
8. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
11. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...gnostic Value of Circulating Tumor Cells, RARITAN...prospective,clinical trial found the number of cir...of progression-free and overall survival among met... report published in the July 1,issue of the Journ... the US, the Netherlands, and the United,Kingdom, ...
(Date:7/24/2008)... 24 /PRNewswire-USNewswire/ -- Headlines claiming ...hole story. The small scale,preliminary study tha...production, is based on recollected intake of soyf.... "This study is confounded by many,issues, thus I...al of,caution," warned Dr. Tammy Hedlund, a resear...
(Date:7/23/2008)...st Approved Systemic Therapy to Treat the Disease ...RNewswire-FirstCall/ --,Bayer HealthCare Pharmaceu...X) today announced that The New England Journal of...onstrating that Nexavar(R) (sorafenib),tablets dec... patients with,unresectable hepatocellular carcino...
(Date:7/23/2008)... Some Areas of the Body Have Greater Concentration... /PRNewswire-USNewswire/ -- Fat removed,from the l...as found to be,an excellent source of stem cells, ...eas of the body, reports a Brazilian-based study i...the official medical journal of the,American Socie...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Soyfoods Do Not Impact Sperm Count 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Data Show Common Allergy Tests Are Not Interchangeable 18816 1Data Show Common Allergy Tests Are Not Interchangeable 18816 2Data Show Common Allergy Tests Are Not Interchangeable 18816 3Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Angiotech to participate in Bank of America Health Care Conference 5229 1Federal polar bear research critically flawed says study in INFORMS journal 3237 1Federal polar bear research critically flawed says study in INFORMS journal 3237 2
... Risk of Late Thrombosis is Minimized with Genous ... -- The efficacy of,OrbusNeich,s Genous(TM) Bio-en...g-eluting stents, while the risk of late thrombosi... an interim,analysis of post-marketing data presen...roPCR 2007 in Barcelona, Spain. , Collected from m...
... PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - ...the publication of a,review validating the utility...unction of the WW domain-containing oxidoreductase...nown involvement,in breast, prostate, lung, pancre...viewed article was published in the online,edition...
Other Medicine Technology:Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 2Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 4
(Date:7/25/2008)... firm represents Pickerington man who contracted E... Kroger store , Columbus,...onaheyohioinjurylawyers.com [The Donahey Law Firm... central Ohio, has filed a product liability lawsu...ainst The Kroger Co., in connection with an E. col...
(Date:7/24/2008)...ital facility on Sand Canyon Avenue , ...08 -- Hoag Memorial Hospital Presbyterian has reac...l Estate Investment Trust headquartered in Long Be... Sand Canyon Avenue near the 405 freeway in Irvine...d by Tenet Healthcare Corporation (NYSE: THC) as I...
(Date:7/24/2008)...stCall/ -- ev3 Inc. (Nasdaq:,EVVV) today announced...and,year-to-date financial results. ev3 will now r...ancial results on Monday, July 28, 2008, after reg... a conference call and webcast at 7:30 a.m.,Centra...9, 2008. ev3,management will review its second qua...
(Date:7/24/2008)...ine Annual Report Experience it at http:/...f., July 24 /PRNewswire/ -- Are you an e-patient?,...users go online for,health information. Thanks to ...re personal health experiences, shop for health ca...Go to http://SutterHealth.org/annualreport ,and y...
Breaking Medicine News(10 mins):Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4
...allergic reaction has been widely reported by wome...in associated with burning in their groin and geni... confirmed by doctors as a true case of allergy th...Thankfully doctors have given the hope to such wom...
...imens to treat HIV infection that are based on a n...TI) are at least as effective as treatment with a ...fewer pills each day, according to a new study fun...are Research and Quality. The study, published in...
... Delhi: The Health and Family Welfare pavilion at ...rated by Dr. Anbumani Ramadoss//, Minister for Hea...he occasion, the Minister said the ambience to the... rural necessities, as their focus in the National...
...is- Scientists from the Mecca of Fashion, Paris, h... the presence of a natural chemical called opiorph... than the well known morphine. In their experiment...in relief with a reduced dosage of this chemical i...
Other Medicine News:Health News:See, men cause allergies in women after sex 2Health News:A More Convenient HIV Treatment Is as Effective as More Complex Regimens 2Health News:A More Convenient HIV Treatment Is as Effective as More Complex Regimens 3
...Ovulation Predicting Test is a qualitative immunoa...e (hLH) in human urine to predict the occurrence o...on of human luteinizing hormone (hLH). Usually, ar...rief, significant rapid increase called the "LH su...
The Shandon Cryotome SME Cryostat model is a sophisticated, top of the line cryostat that combines automated electronic advance and hands-free sectioning with fully independent specimen temperature c
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
The Shandon Varistain Gemini is designed for high throughput, precision, safety, durability and ultimate flexibility in histology and cytology staining applications. It features load-on-demand multip
Medicine Products: